SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b)

(Amendment No.)¹

Targacept, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

87611R306

(CUSIP Number)

January 26, 2007

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b) x Rule 13d-1(c) o Rule 13d-1(d)

¹ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 87611R306	- 13G	Page 2 of 10 Pages
1 NAME OF REPORT Biotechnology Value I.R.S. IDENTIFICAT		
2 CHECK THE APPRC	DPRIATE BOX IF A MEMBER OF A GROUP*	(a) (b)
3 SEC USE ONLY		
4 CITIZENSHIP OR PI Delaware	LACE OF ORGANIZATION	
NUMBER OF	5 SOLE VOTING POWER 0	
SHARES BENEFICIALLY OWNED BY	6 SHARED VOTING POWER 241,130	
EACH REPORTING PERSON	7 SOLE DISPOSITIVE POWER 0	
WITH:	8 SHARED DISPOSITIVE POWER 241,130	
9 AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
241,130		
10 CHECK IF THE AC	GGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
11 PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (9)	
1.3%		
12 TYPE OF REPORT	ING PERSON*	
PN		

CUSIP No. 87611R306		Page 3 of 10 Pages
1 NAME OF REPORT Biotechnology Value I.R.S. IDENTIFICAT		
2 CHECK THE APPRO	DPRIATE BOX IF A MEMBER OF A GROUP*	(a) (b)
3 SEC USE ONLY		
4 CITIZENSHIP OR PI Delaware	LACE OF ORGANIZATION	
NUMBER OF	5 SOLE VOTING POWER 0	
SHARES BENEFICIALLY OWNED BY	6 SHARED VOTING POWER 160,300	
EACH REPORTING PERSON	7 SOLE DISPOSITIVE POWER 0	
WITH:	8 SHARED DISPOSITIVE POWER 160,300	
9 AGGREGATE AM0 160,300	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10 CHECK IF THE AC	GGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
11 PERCENT OF CLA	ASS REPRESENTED BY AMOUNT IN ROW (11)	
0.8%		
12 TYPE OF REPORT	'ING PERSON*	

CUSIP No. 87611R306	13G	Page 4 of 10 Pages
1 NAME OF REPORTI BVF Investments, L. I.R.S. IDENTIFICAT		
2 CHECK THE APPRC	DPRIATE BOX IF A MEMBER OF A GROUP*	(a) 2 (b) c
3 SEC USE ONLY		
4 CITIZENSHIP OR PI Delaware	ACE OF ORGANIZATION	
NUMBER OF	5 SOLE VOTING POWER 0	
SHARES BENEFICIALLY OWNED BY	6 SHARED VOTING POWER 621,800	
EACH REPORTING PERSON	7 SOLE DISPOSITIVE POWER 0	
WITH:	8 SHARED DISPOSITIVE POWER 621,800	
	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
621,800 10 CHECK IF THE AC	GREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	C
11 PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
3.3%		
12 TYPE OF REPORT	ING PERSON*	
00		

CUSIP No. 87611R306	- 13G	Page 5 of 10 Pages
1 NAME OF REPORTI Investment 10, L.L.C I.R.S. IDENTIFICAT		
2 CHECK THE APPRC	DPRIATE BOX IF A MEMBER OF A GROUP*	(a) (b)
3 SEC USE ONLY		
4 CITIZENSHIP OR PI Illinois	LACE OF ORGANIZATION	
NUMBER OF	5 SOLE VOTING POWER 0	
SHARES BENEFICIALLY OWNED BY	6 SHARED VOTING POWER 68,600	
EACH REPORTING PERSON	7 SOLE DISPOSITIVE POWER 0	
WITH:	8 SHARED DISPOSITIVE POWER 68,600	
	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
68,600 10 CHECK IF THE AG	GGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*	
11 PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (11)	
0.4%		
0.4% 12 TYPE OF REPORT	ING PERSON*	

CUSIP No. 87611R306	13G	Page 6 of 10 Pages
1 NAME OF REPOR BVF Partners L.P. I.R.S. IDENTIFICA		
2 CHECK THE APPI	ROPRIATE BOX IF A MEMBER OF A GROUP*	(a) 2 (b) c
3 SEC USE ONLY		
4 CITIZENSHIP OR Delaware	PLACE OF ORGANIZATION	
NUMBER OF	5 SOLE VOTING POWER 0	
SHARES BENEFICIALLY OWNED BY	6 SHARED VOTING POWER 1,091,830	
EACH REPORTING PERSON	7 SOLE DISPOSITIVE POWER 0	
WITH:	8 SHARED DISPOSITIVE POWER 1,091,830	
9 AGGREGATE AN 1,091,830	AOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	C
11 PERCENT OF CL	ASS REPRESENTED BY AMOUNT IN ROW 9	
5.7%		
12 TYPE OF REPOR	TING PERSON*	
PN		

CUSIP No. 87611R306	13G	Page 7 of 10 Pages
1 NAME OF REPORTI BVF Inc. I.R.S. IDENTIFICAT	NG PERSON: ION NO. OF ABOVE PERSON (ENTITIES ONLY):	
2 CHECK THE APPRC	DPRIATE BOX IF A MEMBER OF A GROUP*	(a) x (b) c
3 SEC USE ONLY		
4 CITIZENSHIP OR PI Delaware	LACE OF ORGANIZATION	
NUMBER OF	5 SOLE VOTING POWER 0	
SHARES BENEFICIALLY OWNED BY	6 SHARED VOTING POWER 1,091,830	
EACH REPORTING PERSON	7 SOLE DISPOSITIVE POWER 0	
WITH:	8 SHARED DISPOSITIVE POWER 1,091,830	
9 AGGREGATE AM(1,091,830	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
10 CHECK IF THE AC	GGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*	c
11 PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)	
5.7%		
12 TYPE OF REPORT	ING PERSON*	
IA, CO		

ITEM 1(a). NAME OF ISSUER:

Targacept, Inc. ("Targacept")

ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

200 East First Street, Suite 300 Winston-Salem, North Carolina 27101

ITEM 2(a). NAME OF PERSON FILING:

This Schedule 13G is being filed on behalf of the following persons (the "Reporting Persons"):

- (i) Biotechnology Value Fund, L.P. ("BVF")
- (ii) Biotechnology Value Fund II, L.P. ("BVF2")
- (iii) BVF Investments, L.L.C. ("Investments")
- (iv) Investment 10, L.L.C. ("ILL10")
- (v) BVF Partners L.P. ("Partners")
- (vi) BVF Inc. ("BVF Inc.")

ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:

The principal business office of the persons comprising the group filing this Schedule 13G is located at 900 North Michigan Avenue, Suite 1100, Chicago, Illinois, 60611.

ITEM 2(c).	CITIZENSHIP:

BVF:	a Delaware limited partnership
BVF2:	a Delaware limited partnership
Investments:	a Delaware limited liability company
ILL10:	an Illinois limited liability company
Partners:	a Delaware limited partnership
BVF Inc.:	a Delaware corporation

ITEM 2(d). TITLE OF CLASS OF SECURITIES:

This Schedule 13G is being filed with respect to the common stock, par value \$0.001 per share (the "Common Stock"), of Targacept. The Reporting Persons' percentage ownership of the Common Stock is based on 19,119,745 shares of the Common Stock being outstanding.

As of January 26, 2007, (i) BVF beneficially owns 241,130 shares of Common Stock; (ii) BVF2 beneficially owns 160,300 shares of Common Stock; (iii) Investments beneficially owns 621,800 shares of Common Stock; and (iv) ILL10 beneficially owns 68,600 shares of Common Stock. Beneficial ownership by Partners and BVF Inc. includes 1,091,830 shares of Common Stock.

ITEM 2(e).

CUSIP Number:

87611R306

CUSIP No. 87611R306 13G		Page 9 of 10 Pages	
ITEM 3.		STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), or 13d-2(b) or (c) CHECK WI IS: One of the following	HETHER THE PERSON
	Not applie	cable as this Schedule 13G is filed pursuant to Rule 13d-1(c).	
ITEM 4.	OWNER	SHIP:	
	The inform	mation in items 1 and 5 through 11 on the cover pages (pp. 2 - 7) on this Schedule 13G is hereby	y incorporated by reference.
ITEM 5.	OWNER	SHIP OF FIVE PERCENT OR LESS OF A CLASS:	
		ement is being filed to report the fact that as of the date hereof the reporting person has ceased five percent of the class of securities check the following. o	to be the beneficial owner of
ITEM 6.	OWNER	SHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:	
	Managem those shar beneficial	to the operating agreement of Investments, Partners is authorized, among other things, to invest tent, L.P., the majority member of Investments, in shares of the Common Stock and to vote and res of the Common Stock. Partners and BVF Inc. share voting and dispositive power over share ly owned by BVF, BVF2, Investments and those owned by ILL10, on whose behalf Partners ac rdingly, Partners and BVF Inc. have beneficial ownership of all of the shares of the Common St	exercise dispositive power over s of the Common Stock ts as an investment manager
ITEM 7.		FICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE TED ON BY THE PARENT HOLDING COMPANY:	SECURITY BEING
	Not applie	cable.	
ITEM 8.	IDENTIF	FICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:	
	Not applie	cable.	
ITEM 9.	NOTICE	OF DISSOLUTION OF GROUP:	
	Not applie	cable.	

CUSIP No. 87611R306

ITEM 10. CERTIFICATION

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 5, 2007

BIOTECHNOLOGY VALUE FUND, L.P.

- By: BVF Partners L.P., its general partner
 - By: BVF Inc., its general partner
 - By: /s/ MARK N. LAMPERT

Mark N. Lampert President

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

- By: BVF Inc., its general partner
 - By: /s/ MARK N. LAMPERT

Mark N. Lampert President

BVF INVESTMENTS, L.L.C.

- By: BVF Partners L.P., its manager
 - By: BVF Inc., its general partner
 - By: /s/ MARK N. LAMPERT

Mark N. Lampert President

INVESTMENT 10, L.L.C.

- By: BVF Partners L.P., its attorney-in-fact
 - By: BVF Inc., its general partner
 - By: /s/ MARK N. LAMPERT

Mark N. Lampert President

BVF PARTNERS L.P.

- By: BVF Inc., its general partner
 - By: /s/ MARK N. LAMPERT

Mark N. Lampert President

BVF INC.

By: /s/ MARK N. LAMPERT

Mark N. Lampert President

AGREEMENT REGARDING JOINT FILING

The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, Biotechnology Value Fund II, L.P., a Delaware limited partnership, BVF Investments, L.L.C., a Delaware limited liability company, Investment 10, L.L.C., an Illinois limited liability company, BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the information required by Schedule 13G, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any amendments or supplements thereto shall also be filed on behalf of each of them.

Dated: February 5, 2007

BIOTECHNOLOGY VALUE FUND, L.P.

- By: BVF Partners L.P., its general partner
 - By: BVF Inc., its general partner
 - By: /s/ MARK N. LAMPERT

Mark N. Lampert President

BIOTECHNOLOGY VALUE FUND II, L.P.

- By: BVF Partners L.P., its general partner
 - By: BVF Inc., its general partner
 - By: /s/ MARK N. LAMPERT

Mark N. Lampert President

BVF INVESTMENTS, L.L.C.

- By: BVF Partners L.P., its manager
 - By: BVF Inc., its general partner
 - By: /s/ MARK N. LAMPERT

Mark N. Lampert President

INVESTMENT 10, L.L.C.

- By: BVF Partners L.P., its attorney-in-fact
 - By: BVF Inc., its general partner
 - By: /s/ MARK N. LAMPERT

Mark N. Lampert President

BVF PARTNERS L.P.

- By: BVF Inc., its general partner
 - By: /s/ MARK N. LAMPERT

Mark N. Lampert President

BVF INC.

By: /s/ MARK N. LAMPERT

Mark N. Lampert President